Market Closed -
Nasdaq
01:30:00 01/06/2024 am IST
5-day change
1st Jan Change
2.06
USD
+6.74%
+1.48%
-77.75%
Presentation Operator MessageOperator (Operator)Ladies and gentlemen, good morning, and welcom...
Transcript : Bio-Path Holdings, Inc., Q1 2024 Earnings Call, May 15, 2024
15/05
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
15/05
CI
Bio-Path Closes $1.2 Million Share Offering
19/04
MT
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
18/04
CI
Bio-Path Holdings, Inc. Expands Global Patent Portfolio
15/04
CI
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited
05/04
DJ
Transcript : Bio-Path Holdings, Inc., Q4 2023 Earnings Call, Mar 08, 2024
08/03
North American Morning Briefing : Stock Futures -2-
08/03
DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
08/03
CI
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
10/01
CI
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia
14/12
CI
Transcript : Bio-Path Holdings, Inc., Q3 2023 Earnings Call, Nov 15, 2023
15/11
North American Morning Briefing : Stocks Seen -2-
15/11
DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
15/11
CI
Certain Warrants of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.
01/11
CI
Certain Options of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.
01/11
CI
Certain Common Stock of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.
01/11
CI
Transcript : Bio-Path Holdings, Inc. - Special Call
30/23/30
Transcript : Bio-Path Holdings, Inc., Q2 2023 Earnings Call, Aug 15, 2023
15/23/15
North American Morning Briefing : China Angst -2-
15/23/15
DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
15/23/15
CI
Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
01/23/01
CI
Top Premarket Decliners
26/23/26
MT
Transcript : Bio-Path Holdings, Inc., Q1 2023 Earnings Call, May 12, 2023
12/23/12
North American Morning Briefing : Hopes of Easing -2-
12/23/12
DJ
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
More about the company
Last Close Price
2.06
USD
Average target price
20
USD
Spread / Average Target
+870.87%
Consensus
1st Jan change
Capi.
-77.75% 3.22M +43.36% 54.63B -5.31% 39.92B +14.75% 26.86B -12.56% 26.22B -22.45% 18.78B +25.12% 12.21B +0.04% 12.16B +26.04% 11.94B -11.83% 10.74B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1